Author: Bill Ross | Reading Time: 6 minutes | Published: February 24, 2026 | Updated: March 6, 2026 Acquisitions move fast, leaving companies merged in name but not identity. After a major pharma CDMO acquisition, our client faced inconsistent branding, mixed messages, and poor search visibility for new services. We unified their brand, resulting in a 222% increase in organic traffic and a 30% increase in sales-qualified leads within the first year. At the start of our work together, the client faced issues common in pharmaceutical manufacturing after an acquisition. Both companies had their own brands, websites, and ways of describing services, yet neither approach matched what the combined business truly offered. Their search presence was fragmented. Some pages ranked for the original company’s services, others for the acquired company’s capabilities. Because both sites targeted similar keywords, they competed and weakened search authority, causing confusion about the full range of services. Brand elements—logo, colors, typography, and messaging style—differed between the companies. Sales teams used varying materials. The website listed outdated services, and new capabilities, such as expanded drug substance manufacturing and formulation development, were missing. These gaps prevented search engines from recognizing all services.
After an acquisition, a CDMO has a short period to define its new brand before clients and prospects become confused. Companies that unify their identity and update content quickly usually gain early search authority in their new market. Those who wait may spend years trying to catch up. – Emulent Strategy Team
We also found major gaps in how the site connected to important topics, failing to apply modern entity-based SEO principles (e.g., related topics and terms to signal expertise). The content rarely linked the client to key areas that search engines expect from reputable CDMOs, such as regulatory compliance (following government rules), FDA submission support (helping with documents for U.S. Food and Drug Administration approval), analytical testing (lab tests to check drug quality), clinical manufacturing (making drugs for clinical trials), and scale-up services (increasing production from lab to commercial levels). These connections were either missing or hidden in technical language that search engines could not easily understand. We handled this project in three steps: brand identity, website structure, and content/SEO. Each step depended on the one before. The SEO work needed a solid website, and the website needed a clear brand identity as its foundation. We began the brand work with a discovery sprint. We reviewed how both original companies presented themselves. We looked at what their clients valued and where the combined company could stand out in the pharmaceutical contract manufacturing field. Sponsor companies—biotech and pharma firms that outsource development and manufacturing—look for signs like technical expertise, regulatory experience, flexibility, and a proven track record. Neither of the old brands clearly communicated these strengths. The core elements of the brand identity work included: After finalizing the brand identity, we planned the website by combining the two old sites. We chose which content to keep, rewrite, or remove, ensuring every service page matched the new positioning. This project went beyond a standard redesign since we had to merge two sites and clearly show the expanded services. Each page had to explain services to sponsor companies and provide enough detailed content for search engines to understand the CDMO’s offerings and audience. We mapped the information architecture for the main service categories that matter to CDMO clients: drug substance development, drug product development, analytical services, clinical manufacturing, and commercial manufacturing. Each category has its own section with dedicated pages, rather than the single-page service overviews used before.
CDMOs often have strong scientific expertise but struggle to convey their value to decision-makers. Their website content can become overly technical. Our role is to translate that knowledge into clear, accessible information for sponsors and to ensure key topics are included in search results. – Emulent Strategy Team
The key website elements we built or rebuilt included: We focused on organizing the site’s information clearly. CDMOs get specific search queries from targeted audiences who often compare several options. The website needed to make it easy for users to find what they needed and to show why the company stood out. Content development ran parallel to design and development. We started by creating an entity map for core topic areas, identifying key pharmaceutical manufacturing concepts, regulatory bodies (e.g., the FDA), process types (e.g., different methods of drug production), and technology categories. This entity-and-semantic-SEO (using structured content and topic relationships to improve search rankings) structure is standard in our complex B2B and technical-industry work. We used NLP analysis on the old content to see which important topics were included and which were missing. The results were clear. The site talked about drug product manufacturing in broad terms but rarely linked these services to specific dosage forms, regulatory steps, or process stages in a way search engines could understand. So, while the site seemed thorough to a casual reader, search engines saw it as lacking detail and authority. The content rebuild covered three categories. First, we created foundational pages for every major service area using structured content. We placed key entity pairs (related business terms or topics) close together. This connects services to the regulatory context, technical processes, and client outcomes that sponsor companies search for. Second, we developed supporting blog and resource content to build topical depth across categories such as process development, scale-up, and CMC consulting. Third, we wrote technical FAQ content addressing the specific questions CDMO evaluators ask during vendor selection.
In the pharma and life sciences sector, companies frequently write content aimed at internal teams, using language that may not resonate with potential biotech clients. Addressing this language gap and aligning content with actual search behavior leads to significant traffic improvements. – Emulent Strategy Team
The content types we produced and their strategic purpose: We also applied the SEO strategies for pharmaceutical and life sciences companies we have developed across similar engagements, which shaped how we handled technical terminology, regulatory language, and the balance between accessibility and scientific credibility throughout the content. The 222% growth in organic traffic was a clear result, but the improvement in lead quality was even more important. A 30% increase in sales-qualified leads showed that the right visitors were finding the site, understanding the services, and reaching out. For a CDMO, this matters most, since one client can mean millions in revenue over several years. Search visibility increased the most in the service areas where we created the most detailed content. Pages about solid oral dosage form development, analytical method validation, and clinical-stage manufacturing saw the biggest improvements. These were the topics missing from the old content, so they had the greatest potential for growth. The unified brand also brought benefits beyond search results. The sales team noticed that conversations with prospects started at a more detailed level because visitors had already read in-depth service information online, not just brief descriptions. Trade show follow-ups also converted better because the website supported what the sales team shared in person. This project confirmed some lessons we’ve seen in other pharmaceutical and life sciences work. First, delaying brand consolidation after an acquisition comes at a cost. Every month a company runs two separate or outdated websites, it loses search authority that can’t be regained. Companies that act quickly and rebuild their digital presence tend to gain more ground faster. Second, entity-based SEO is especially important in technical fields like pharmaceutical contract services. Search engines rely on these connections when ranking complex B2B content. A page that talks about drug substance manufacturing but does not link it to regulatory, analytical, and process development topics will not perform as well as one that does. This is not about keyword stuffing, but about writing content that matches how the topic works in real life. Third, brand clarity and search performance go hand in hand. A consistent brand with clear service descriptions gives writers and SEO teams better material to use. The sooner the brand is defined, the faster the rest of the work can progress.
“The brands we see struggle the most after acquisitions are the ones that treat marketing as something to figure out after everything else is settled. The companies that treat brand and digital presence as part of the integration plan from day one come out of it with real competitive advantages in their category.” – Strategy Team, Emulent Marketing.
This project included brand identity, website design, content strategy, and entity SEO and semantic optimization for a complex post-acquisition situation. We achieved results by treating all these parts as a single, connected effort, not as separate tasks. If your pharmaceutical company, CDMO, or life sciences organization faces similar challenges—such as a post-acquisition rebrand, a website that is not generating qualified leads, or a search presence that does not reflect your actual services—we can help you create and execute a structured plan. Our experience in pharmaceutical marketing, life sciences marketing, and digital transformation for pharma brands gives us a solid understanding of what sponsor companies want and how search engines judge technical content. Reach out to the Emulent team to talk about your pharmaceutical marketing needs and find the best starting point for your organization. How We Unified a Pharma CDMO’s Brand Post-Acquisition and Grew Organic Traffic 222%
What Does a Post-Acquisition Brand Problem Look Like for a Pharma CDMO?
How Did We Structure the Brand Unification Strategy?
What Did the Website Redesign Actually Require?
How Did the Content Strategy Address Entity and Semantic SEO Gaps?
What Did the Results Look Like After 12 Months?
What Are the Broader Lessons for CDMOs Going Through Acquisitions?
How the Emulent Team Can Help With Your Pharmaceutical Marketing
